Literature DB >> 7805233

Myocardial perfusion imaging with 99mTc tetrofosmin. Comparison to 201Tl imaging and coronary angiography in a phase III multicenter trial. Tetrofosmin International Trial Study Group.

B L Zaret1, P Rigo, F J Wackers, R C Hendel, S H Braat, A S Iskandrian, B S Sridhara, D Jain, R Itti, A N Serafini.   

Abstract

BACKGROUND: Our objective was to compare the sensitivity and specificity of tetrofosmin, a new 99mTc-labeled myocardial perfusion imaging agent for the detection of myocardial perfusion abnormalities, with those of 201Tl and coronary angiography. Our hypothesis was that same-day stress/rest tetrofosmin imaging could provide data comparable to those of 201Tl imaging. Myocardial perfusion imaging plays an important role for the evaluation of coronary artery disease. Newer 99mTc-labeled agents offer several advantages over 201Tl, the conventional myocardial perfusion imaging agent. Tetrofosmin is a new 99mTc-labeled agent with promising results in preliminary studies. METHODS AND
RESULTS: Two hundred fifty-two patients with suspected coronary artery disease were enrolled in 10 centers in the United States and Europe. All patients underwent exercise and rest myocardial perfusion imaging with 99mTc-tetrofosmin using two separate injections of the radiotracer 4 hours apart on the same day. Planar images were obtained in three standard views 15 to 60 minutes after radiotracer injection. Patients also underwent standard exercise and redistribution planar 201Tl imaging within 2 weeks of tetrofosmin imaging. In addition, 58 healthy subjects with low likelihood of coronary artery disease underwent exercise and rest tetrofosmin imaging. Coronary angiograms were available in 181 patients with suspected coronary artery disease. All radionuclide images were processed in the central core laboratory and interpreted blindly by a panel of four experienced readers. 201Tl images and tetrofosmin images were read separately. Discrepancies were resolved by consensus. The workload, peak heart rate, and double products were comparable during exercise for both imaging agents. Technically acceptable paired 201Tl and tetrofosmin images were available in 224 of 252 patients. Tetrofosmin images were generally of good quality, with low extracardiac activity, and easy to interpret. Patients were categorized as showing normal, ischemia, infarction, or mixture with each imaging modality. Precise concordance for each of these categories was 59.4% (kappa = 0.44; 95% CI, 0.35 to 0.53). When patients were categorized as normal or abnormal, the concordance was 80.4% (kappa = 0.55; 95% CI, 0.43 to 0.67). When each of five anatomic territories (septal, anterior, inferior, lateral, and apical) was categorized as normal versus abnormal, the concordance varied from 81% to 90%. When similar comparison was made for the specific category of abnormality, the concordance was 64% to 84%. When coronary angiography was used as the criterion, the sensitivity and positive and negative predictive accuracy of tetrofosmin and 201Tl were comparable. The normalcy rate of tetrofosmin images in the healthy subjects with low likelihood of coronary artery disease was 97%.
CONCLUSIONS: 99mTc tetrofosmin is a new myocardial imaging agent with favorable imaging characteristics with results comparable to those of 201Tl.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7805233     DOI: 10.1161/01.cir.91.2.313

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  45 in total

Review 1.  An overview of radiotracers in nuclear cardiology.

Authors:  W Acampa; C Di Benedetto; A Cuocolo
Journal:  J Nucl Cardiol       Date:  2000 Nov-Dec       Impact factor: 5.952

2.  Evaluation of left ventricular wall motion, volumes, and ejection fraction by gated myocardial tomography with technetium 99m-labeled tetrofosmin: a comparison with cine magnetic resonance imaging.

Authors:  P Vaduganathan; Z X He; G W Vick; J J Mahmarian; M S Verani
Journal:  J Nucl Cardiol       Date:  1999 Jan-Feb       Impact factor: 5.952

Review 3.  Comparison of Tl-201 with Tc-99m-labeled myocardial perfusion agents: technical, physiologic, and clinical issues.

Authors:  P Kailasnath; A J Sinusas
Journal:  J Nucl Cardiol       Date:  2001 Jul-Aug       Impact factor: 5.952

Review 4.  Quantification of SPECT myocardial perfusion imaging.

Authors:  Wanda Acampa; Wei He; Carmine di Nuzzo; Alberto Cuocolo
Journal:  J Nucl Cardiol       Date:  2002 May-Jun       Impact factor: 5.952

5.  Application of pixel truncation to reduce intensity artifacts in myocardial SPECT imaging with Tc-99m tetrofosmin.

Authors:  Masao Funahashi; Tsuyoshi Shimonagata; Kazuhiro Mihara; Kazuyuki Kashiyama; Ryuichi Shimizu; Shuzo Machida; Kazuyuki Izumi; Hideo Kusuoka; Tsunehiko Nishimura; Noritake Hoki; Sei-Ichi Kawamoto
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

6.  Impact of hypertension on the accuracy of exercise stress myocardial perfusion imaging for the diagnosis of coronary artery disease.

Authors:  A Elhendy; R T van Domburg; F B Sozzi; D Poldermans; J J Bax; J R Roelandt
Journal:  Heart       Date:  2001-06       Impact factor: 5.994

7.  Improved diagnostic accuracy of planar imaging with technetium 99m-labeled tetrofosmin compared with thallium-201 for the detection of coronary artery disease.

Authors:  R S Khattar; R C Hendel; J C Crawley; F J Wackers; P Rigo; B L Zaret; B S Sridhara; A Lahiri
Journal:  J Nucl Cardiol       Date:  1997 Jul-Aug       Impact factor: 5.952

8.  Advances in myocardial perfusion imaging.

Authors:  James E Udelson
Journal:  J Nucl Cardiol       Date:  2012-02       Impact factor: 5.952

9.  Multi-vessel disease and CZT SPECT. Comparison with coronary angiography.

Authors:  Nikant Sabharwal; Avijit Lahiri
Journal:  J Nucl Cardiol       Date:  2016-02-17       Impact factor: 5.952

Review 10.  Role of myocardial perfusion imaging for risk stratification in suspected or known coronary artery disease.

Authors:  N K Sabharwal; A Lahiri
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.